NF-κB-IN-4 (compound 17) is a potent NF-κB pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research [1].
In Vitro, NF-κB-IN-4 (compound 17) (0-10 μM, 24 h) shows high anti-inflammatory activity[1]. NF-κB-IN-4 (0-5 μM, 24 h) significantly decreases the LPS-induced p-IκBα expression levels, significantly inhibits the phosphorylation of IκBα and the expression of three proteins (NLRP3, ASC and caspase-1) in BV2 cells[1]. NF-κB-IN-4 (0-5 μM, 24 h) induces LPS-induced apoptosis in BV2 cells in a dose-dependent manner[1].
References:
[1]. Zhang XF, et al. Anti-neuroinflammatory effects of novel 5,6-dihydrobenzo[h]quinazolin-2-amine derivatives in lipopolysaccharide-stimulated BV2 microglial cells. Eur J Med Chem. 2022;235:114322.
In Vitro, NF-κB-IN-4 (compound 17) (0-10 μM, 24 h) shows high anti-inflammatory activity[1]. NF-κB-IN-4 (0-5 μM, 24 h) significantly decreases the LPS-induced p-IκBα expression levels, significantly inhibits the phosphorylation of IκBα and the expression of three proteins (NLRP3, ASC and caspase-1) in BV2 cells[1]. NF-κB-IN-4 (0-5 μM, 24 h) induces LPS-induced apoptosis in BV2 cells in a dose-dependent manner[1].
References:
[1]. Zhang XF, et al. Anti-neuroinflammatory effects of novel 5,6-dihydrobenzo[h]quinazolin-2-amine derivatives in lipopolysaccharide-stimulated BV2 microglial cells. Eur J Med Chem. 2022;235:114322.